Disappointing results see Vigil Neuro drop iluzanebart development

US clinical-stage biotech Vigil Neuroscience (Nasdaq: VIGL) today announced a disappointing update on the Phase II IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20mg/kg and 40mg/kg dose cohorts. The Phase II IGNITE trial showed no beneficial effects on biomarker or clinical efficacy endpoints with treatment of iluzanebart in ALSP patients. Based upon these results, the Phase II long-term extension study is being discontinued in accordance with the process previously disclosed.

“We have worked diligently over the past five years advancing our ALSP program in pursuit of a potentially effective therapy for this devastating neurodegenerative disease. Through every step, we have been deeply inspired by and profoundly grateful for the ALSP community, including patients and their families, patient advocacy groups, physicians, and trial investigators, whose courage, commitment, and partnership have been essential to driving this work forward,” said Ivana Magovčević-Liebisch, president and chief executive of Vigil.